Who are Oruka Therapeutics, Inc.'s main suppliers?

Oruka Therapeutics, Inc. (ORKA) key suppliers include: CMOS, PARAGON, Halozyme Therapeutics, Inc., MoonLake Immunotherapeutics, MoonLake Immunotherapeutics. View the full supplier network at chainsifter.com/chain/ORKA.

Who are Oruka Therapeutics, Inc.'s major customers?

Oruka Therapeutics, Inc. (ORKA) key customers include: MoonLake Immunotherapeutics, MoonLake Immunotherapeutics. View the full customer network at chainsifter.com/chain/ORKA.

What sector is Oruka Therapeutics, Inc. in?

Oruka Therapeutics, Inc. (ORKA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ORKA Supply Chain: Oruka Therapeutics, Inc. Supplier List & 10 Relationships

5Suppliers

2Customers

3Debt Items

20Related Chains

Oruka Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CMOS	CMOS	92%	we currently rely on CMOs to manufacture our product candidates
PARAGON	PARAGON	90%	Pursuant to the terms of each of the License Agreements, we are obligated to pay Paragon non-refundable milestone payments of up to $12.0 million under each respective agreement upon the achievement …
HALO	Halozyme Therapeutics, Inc.	85%	Reciprocal relationship from HALO graph: les of five commercial products from the Roche collaboration, two commercial products from the Janssen collaboration and one commercial product from each of t…
MLTX	MoonLake Immunotherapeutics	72%	ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any ap…
MLTX	MoonLake Immunotherapeutics	72%	Reciprocal relationship from MLTX graph: LK through Phase 3 development and regulatory approval will require us to expand commercialization preparation activities and incur related expenses before we…

Oruka Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
MLTX	MoonLake Immunotherapeutics	72%	ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in 2045, absent any ap…
MLTX	MoonLake Immunotherapeutics	72%	Reciprocal relationship from MLTX graph: Reciprocal relationship from ORKA graph: ant to license agreements with Paragon. If the patent applications mature into one or more issued patents covering OR…

Oruka Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
ORKA-DEBT	Debt stack $1.8M	90%	Market cache reports total debt of $1.8M.
ORKA-DEBT-11592	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.
ORKA-DEBT-11591	Warrants outstanding: 315356	90%	xbrl warrant detail from xbrl 2025-12-31.

Oruka Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Oruka Therapeutics, Inc..

Oruka Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
ORKA-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 188 tracked holders.

Oruka Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ATOS	Atossa Therapeutics, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
AMPH	Amphastar Pharmaceuticals, Inc.	100.00	2

Oruka Therapeutics, Inc. Supply Chain